Epitope mapping

IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments

Retrieved on: 
Wednesday, March 20, 2024
Research, General Health, Pharmaceutical, Technology, Infectious Diseases, Artificial Intelligence, Health Technology, Science, Biotechnology, Neurology, Other Science, Health, Drug discovery, Acquisition, Doctor of Philosophy, LSA, Epitope mapping

IPA remains committed to expanding its contract research organization (CRO) capabilities and leveraging technology to drive innovation and efficiency, particularly in AI-driven drug design.

Key Points: 
  • IPA remains committed to expanding its contract research organization (CRO) capabilities and leveraging technology to drive innovation and efficiency, particularly in AI-driven drug design.
  • Carterra’s LSA instrument delivers significant throughput in short time frames requiring only small sample volumes.
  • “It represents a strategic move to capture the growing interest in and huge potential of AI-driven drug discovery and digital biology.
  • “The LSA has made the use of AI in antibody discovery a reality; nothing generates more data in as little time to train AI/ML engines.”

Icosagen Acquires the Carterra LSA Instrument to Significantly Enhance Its Antibody Screening Capabilities in the Discovery and Development of New Therapeutic and Diagnostic Antibodies

Retrieved on: 
Monday, March 20, 2023
Health, Pharmaceutical, GMP, Contract manufacturing organization, ICF, Biotechnology, CHO, LSA, Antibody, Microfluidics, Protein, Acquisition, Contract research organization, Epitope mapping, Mab, Drug discovery, FDA, Kinetics, NIH, ChromeOS, Software, Fine chemical, Boron group

Services cover up to early clinical candidate development, including stable CHO cell line development for 50L to 1000L GMP production runs.

Key Points: 
  • Services cover up to early clinical candidate development, including stable CHO cell line development for 50L to 1000L GMP production runs.
  • The acquisition of the Carterra LSA technology will significantly enhance the flexibility and throughput of antibody screening and characterization.
  • Carterra’s LSA will enable ICF to speed up and significantly enhance its end-to-end service capabilities for global biotechnology and pharmaceutical customers.
  • “This collaboration will speed our discovery and development efforts saving us time and significantly enhancing our antibody screening capabilities.

Twist Bioscience Announces Robust Antibody Discovery Services Integrating In Vivo, In Vitro and In Silico Approaches

Retrieved on: 
Thursday, March 9, 2023
Health, Technology, Nanotechnology, Research, Science, Pharmaceutical, Biotechnology, MBA, Biogen, CSO, G protein-coupled receptor, Factory, Engineering, Acquisition, Workflow, Martek Biosciences Corporation, Epitope mapping, Antibody, Integration, Silicon, Machine learning, DNA, Business, Technology transfer, Twist Bioscience, VHH, Quantic School of Business and Technology, Doctor of Philosophy, Acceleration, Spacecraft, AI, Festival, Future, Massachusetts Institute of Technology, Immunoglobulin G, Management, Vaccine, Library, Immunization

The combined team will be led by Tracey Mullen, MBA, who was appointed senior vice president of biopharma for Twist Bioscience.

Key Points: 
  • The combined team will be led by Tracey Mullen, MBA, who was appointed senior vice president of biopharma for Twist Bioscience.
  • “By integrating our platforms into a robust service menu, we now offer premium throughput, resolution and speed to customers looking to outsource antibody discovery and optimization,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • Supported by high-throughput DNA synthesis and IgG antibody production, Twist constructs large and highly specific synthetic antibody libraries with discovery beginning with either in vivo or in vitro diversity.
  • The integrated offering of antibody discovery services will be highlighted at the Festival of Biologics occurring March 20-22, 2023 in San Diego.

Adagio Therapeutics, Inc.: Please contact the Portnoy Law Firm to recover your losses; April 3, 2023 deadline

Retrieved on: 
Thursday, February 16, 2023
Therapy, Epitope mapping, Class, Omicron, Cryptocurrency, Adagio

​LOS ANGELES, Feb. 16, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Invivyd, Inc. f/k/a Adagio Therapeutics, Inc (“Adagio”) (NASDAQ: IVVD, ADGI) investors that a lawsuit filed on behalf of investors that purchased Adagio (NASDAQ: IVVD, ADGI) securities between November 29, 2021 and December 14, 2021, both dates inclusive (the "Class Period").

Key Points: 
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 844-767-8529 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.
  • The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors.

Caris Life Sciences Announces the Expansion of Caris Discovery to Accelerate Development of Novel Precision Therapeutics to Combat Cancer

Retrieved on: 
Thursday, January 5, 2023
Cancer, Health, DNA, Foot, Traction, MBA, ADAPT, Disease, Patient, NK, Histology, Quality of life, Senior, Epitope mapping, Pharmaceutical industry, Medical imaging, Vaccine

IRVING, Texas, Jan. 5, 2023 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, today announced the expansion of Caris Discovery, a proprietary, multi-omics target discovery engine designed to unlock otherwise inaccessible targets in areas of high unmet clinical need, with a goal of delivering transformational patient impact.

Key Points: 
  • "Despite numerous breakthroughs in oncology, many patients with cancer desperately need novel medicines to improve their outcomes and quality of life.
  • Discovering new cancer medicines remains extremely challenging, and one of the biggest stumbling blocks is the scarcity of viable targets," said David Spetzler , M.S., Ph.D., MBA, President and Chief Scientific Officer of Caris Life Sciences.
  • "Historically, the vast majority of potential drug targets were considered undruggable," said Milan Radovich , Ph.D., Senior Vice President and Chief Precision Medicine Officer of Caris Life Sciences.
  • Just five months later, Caris and Xencor expanded their target discovery collaboration to broaden the scope to additional cancer types with significant unmet need.

LifeMD and Cleared Offer New Hope to Allergy Patients Through Strategic Partnership With Allergenis

Retrieved on: 
Monday, August 22, 2022
Partnership, EAACI, Patient, Epitope mapping, Security (finance), CEO, Food, Securities Exchange Act of 1934, Caregiver, Securities Act of 1933, NASDAQ, Peanut allergy, Food allergy, Overalls, Parent, Drug Quality and Security Act, Blood, Standard of care, Anxiety, LinkedIn, Asthma, Diagnosis, Mount Sinai, Forward-looking statement, Icahn School of Medicine at Mount Sinai, Journal, U.S. Securities and Exchange Commission, Immunology, CLIA, European Academy of Allergy and Clinical Immunology, GLOBE, Instagram, Database, JAMA Pediatrics, Clear, Company, OFC, Twitter, News, LFMD, Risk, Terminology, Annual report, Private Securities Litigation Reform Act, Review, Marketing, William Frankland (allergist), Child, Â, Medical device, Vaccine, Health insurance, Hospital, Risk management, Medicine, Allergy, Facebook

The strategic partnership leverages Cleareds direct-to-patient allergy telehealth infrastructure and marketing expertise and Allergenis breakthrough peanut allergy diagnostic blood test.

Key Points: 
  • The strategic partnership leverages Cleareds direct-to-patient allergy telehealth infrastructure and marketing expertise and Allergenis breakthrough peanut allergy diagnostic blood test.
  • The partnership also establishes Cleared as the exclusive telehealth provider for the commercial launch of Allergenis highly accurate peanut allergy diagnostic in the direct-to-consumer channel.
  • The partnership sets a new standard in food allergy management with Allergenis novel, low-risk and non-invasive peanut allergy diagnostic blood test.
  • The Allergenis peanut allergy diagnostic is potentially life-changing for food allergy patients, who have had to rely on a potentially risky and often anxiety-producing procedure called an oral food challenge to rule out a food allergy, said LifeMD CEO Justin Schreiber.

Aviva Systems Biology Announces the Launch of High Throughput Antibody Characterization Services

Retrieved on: 
Monday, April 11, 2022
SPR, IHC, Research, Immunoprecipitation, ELISA, Aviva, Epitope mapping, Time, A-DNA, Antibody, SAN, Proteomics, Fine chemical, Vaccine

SAN DIEGO, April 11, 2022 /PRNewswire/ -- Aviva Systems Biology , a market leader in antibodies, immunoassay kits, and recombinant proteins for life science research, today announced the launch of its new service offering for high throughput Antibody Characterization Services .

Key Points: 
  • SAN DIEGO, April 11, 2022 /PRNewswire/ -- Aviva Systems Biology , a market leader in antibodies, immunoassay kits, and recombinant proteins for life science research, today announced the launch of its new service offering for high throughput Antibody Characterization Services .
  • Aviva Systems Biology's Antibody Characterization Services provides drug discovery researchers in small to mid-size biotechs with an affordable and easily accessible solution for rapid screening of therapeutic antibodies, kinetic analysis, and epitope mapping and binning.
  • By leveraging the advanced Carterra LSA platform, Aviva can provide high throughput SPR analysis for biotherapeutic antibody development at a scale other screening providers can't match.
  • We are excited to offer this unique solution to biotherapeutic antibody researchers," said Kevin Harvey, President of Aviva Systems Biology.

Integral Molecular Expands Partnership with Japan's Life Sciences Distributor Funakoshi to Provide Access to Antibody Specificity and Epitope Mapping Services

Retrieved on: 
Tuesday, June 8, 2021
Medical specialties, Immunologic tests, Medicine, Clinical medicine, Immunology, Antigenic determinant, Epitope mapping, Antibody, Epitope

PHILADELPHIA, June 8, 2021 /PRNewswire/ -- Integral Molecular has expanded its partnership with Funakoshi, a leader in distributing life science research reagents and services, to be the exclusive provider of Integral Molecular's therapeutic antibody characterization technologies in Japan.

Key Points: 
  • PHILADELPHIA, June 8, 2021 /PRNewswire/ -- Integral Molecular has expanded its partnership with Funakoshi, a leader in distributing life science research reagents and services, to be the exclusive provider of Integral Molecular's therapeutic antibody characterization technologies in Japan.
  • The partnership will provide researchers with access to antibody characterization technologies optimized to deliver IND-ready results in as little as 4 weeks, including off-target specificity profiling using the Membrane Proteome Array and high-resolution epitope mapping using Shotgun Mutagenesis .
  • Detailed specificity and epitope analysis are critical for therapeutic antibody success and intellectual property protection.
  • "We have a long-standing partnership with Integral Molecular, having distributedtheir Lipoparticle products for more than 8 years," said Tetsuya Ikeda, President and CEO of Funakoshi.

Serimmune Launches COVID Antibody Epitope Mapping Service

Retrieved on: 
Thursday, March 11, 2021
Medical specialties, Branches of biology, Clinical medicine, Immunology, Immune system, Immunologic tests, Glycoproteins, Antigenic determinant, Epitope mapping, Antibody, Epitope, Anti-SSA/Ro autoantibodies

GOLETA, Calif., March 11, 2021 /PRNewswire/ -- Serimmune Inc., a leader in understanding the functional antibody repertoire's role in human disease, today announced the launch of a COVID antibody epitope mapping discovery service.

Key Points: 
  • GOLETA, Calif., March 11, 2021 /PRNewswire/ -- Serimmune Inc., a leader in understanding the functional antibody repertoire's role in human disease, today announced the launch of a COVID antibody epitope mapping discovery service.
  • This offering now provides academic and biopharma researchers with ready access to Serimmune's proprietary Serum Epitope Repertoire Analysis (SERA) technology.
  • "We have collaborated with Serimmune throughout the pandemic to characterize the humoral response to SARS-CoV-2," saidDr.
  • Serimmune is a leader in understanding antibody repertoire and is focused on identifying and exploiting the universe of relationships between antibodies and antigens.

OXGENE Introduces SLIM Platform for Discovery of Antibodies Against Membrane Proteins

Retrieved on: 
Tuesday, January 12, 2021
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Branches of biology, Biology, Medical specialties, Immunology, Glycoproteins, Antibody, Immune system, Epitope, Cell membrane, Integral membrane protein, Epitope mapping, Bacterial display

OXGENE, a biotechnology company offering integrated discovery and manufacturing technologies to the cell and gene therapy industry, announces the introduction of its self-labelling integral membrane (SLIM) protein discovery system.

Key Points: 
  • OXGENE, a biotechnology company offering integrated discovery and manufacturing technologies to the cell and gene therapy industry, announces the introduction of its self-labelling integral membrane (SLIM) protein discovery system.
  • In SLIM display, a target membrane protein and a library of potential binders are expressed in the same mammalian cells.
  • Discovering antibodies against integral membrane proteins can be challenging as most of the protein sits within the membrane itself, leaving reduced surface exposed epitopes above the cell membrane for antibody binding.
  • OXGENEs SLIM mammalian display system is designed to overcome these obstacles by discovering antibodies against complex membrane proteins in their native configuration.